Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ versus VELOSEF 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ versus VELOSEF 125.
FORTAZ vs VELOSEF '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
Cephalexin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking, leading to cell lysis.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day for serious infections.
500 mg orally every 6 hours for uncomplicated infections; 1 g orally every 6 hours for more severe infections.
None Documented
None Documented
2 hours (normal renal function); prolonged to 12-20 hours in ESRD
Terminal elimination half-life: 0.5-1.0 hour (normal renal function); prolonged to 10-20 hours in severe renal impairment (CrCl <10 mL/min)
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; 5-10% biliary/fecal
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic